Latest News-SIMCERE PHARMACEUTICAL GROUP Mediaroom_Page

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced ...

2024-12-04 18:10 1488

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

World Stroke Congress | TASTE-2 significantly reduces stroke disability

NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (20...

2024-10-30 15:36 1281

World Stroke Congress | TASTE-2 significantly reduces stroke disability

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative st...

2024-10-25 15:14 1191

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group ...

2024-09-14 19:43 3533

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group L...

2024-09-05 13:49 1231

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative...

2024-09-02 20:24 1588

Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative onco...

2024-06-26 12:36 1605

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC),...

2024-05-21 15:52 1332

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the Journal of American Medical...

2024-02-21 12:26 2397

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group L...

2023-11-23 16:04 4520

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company

-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total r...

2023-04-24 18:09 2420

Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma

NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simc...

2023-03-14 20:00 2579

First Prescription for COSELA® (trilaciclib) Issued in China

- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital...

2023-02-09 21:00 3025

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced toda...

2022-12-20 19:21 2148

Simcere and Idorsia enter into a licensing agreement for daridorexant in China

NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere")...

2022-11-16 08:32 3398

Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237

Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oc...

2022-10-27 21:25 2211

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

* Simcere will receive a $15 million upfront payment, and up to $492 million in development and c...

2022-09-29 11:32 1495

Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue

NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announ...

2022-09-05 13:09 3551

Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group

NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group announces today the appo...

2022-09-05 13:08 2550

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096) announced that SIM0417, a candida...

2022-05-18 11:56 2160